Schrenk D - Search Results

1

Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression.

Kauffmann HM, Pfannschmidt S, Zöller H, Benz A, Vorderstemann B, Webster JI, Schrenk D. Kauffmann HM, et al. Among authors: schrenk d. Toxicology. 2002 Feb 28;171(2-3):137-46. doi: 10.1016/s0300-483x(01)00570-4. Toxicology. 2002. PMID: 11836020

2

Assessment of biological activities of mixtures of polychlorinated dibenzo-p-dioxins (PCDDs) and their constituents in human HepG2 cells.

Lipp HP, Schrenk D, Wiesmüller T, Hagenmaier H, Bock KW. Lipp HP, et al. Among authors: schrenk d. Arch Toxicol. 1992;66(3):220-3. doi: 10.1007/BF01974019. Arch Toxicol. 1992. PMID: 1497488

3

Assessment of biological activities of mixtures of polychlorinated dibenzo-p-dioxins: comparison between defined mixtures and their constituents.

Schrenk D, Lipp HP, Wiesmüller T, Hagenmaier H, Bock KW. Schrenk D, et al. Arch Toxicol. 1991;65(2):114-8. doi: 10.1007/BF02034936. Arch Toxicol. 1991. PMID: 1647757

4

Potency of mixtures of polychlorinated biphenyls as inducers of dioxin receptor-regulated CYP1A activity in rat hepatocytes and H4IIE cells.

Schmitz HJ, Hagenmaier A, Hagenmaier HP, Bock KW, Schrenk D. Schmitz HJ, et al. Among authors: schrenk d. Toxicology. 1995 May 5;99(1-2):47-54. doi: 10.1016/0300-483x(94)02994-6. Toxicology. 1995. PMID: 7762001

5

Metabolic activation of 2-acetylaminofluorene is required for induction of multidrug resistance gene expression in rat liver cells.

Schrenk D, Gant TW, Michalke A, Orzechowski A, Silverman JA, Battula N, Thorgeirsson SS. Schrenk D, et al. Carcinogenesis. 1994 Nov;15(11):2541-6. doi: 10.1093/carcin/15.11.2541. Carcinogenesis. 1994. PMID: 7955103

6

Drug-metabolizing enzyme activities in freshly isolated oval cells and in an established oval cell line from carcinogen-fed rats.

Steinberg P, Steinbrecher R, Schrenk D, Munzel P, Bruck M, Gschaidmaier H, Oesch F, Bock KW. Steinberg P, et al. Among authors: schrenk d. Cell Biol Toxicol. 1994 Feb;10(1):59-65. doi: 10.1007/BF00757187. Cell Biol Toxicol. 1994. PMID: 8076223

7

TCDD-inducible plasminogen activator inhibitor type 2 (PAI-2) in human hepatocytes, HepG2 and monocytic U937 cells.

Gohl G, Lehmköster T, Münzel PA, Schrenk D, Viebahn R, Bock KW. Gohl G, et al. Among authors: schrenk d. Carcinogenesis. 1996 Mar;17(3):443-9. doi: 10.1093/carcin/17.3.443. Carcinogenesis. 1996. PMID: 8631129

8

Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone.

Schrenk D, Michalke A, Gant TW, Brown PC, Silverman JA, Thorgeirsson SS. Schrenk D, et al. Biochem Pharmacol. 1996 Nov 8;52(9):1453-60. doi: 10.1016/s0006-2952(96)00512-6. Biochem Pharmacol. 1996. PMID: 8937457

9

Interactions of TCDD with signal transduction and neoplastic development in c-myc transgenic and TGF-alpha transgenic mice.

Schrenk D, Müller M, Merlino G, Thorgeirsson SS. Schrenk D, et al. Arch Toxicol Suppl. 1997;19:367-75. doi: 10.1007/978-3-642-60682-3_35. Arch Toxicol Suppl. 1997. PMID: 9079224 No abstract available.

10

Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes.

Kauffmann HM, Keppler D, Kartenbeck J, Schrenk D. Kauffmann HM, et al. Among authors: schrenk d. Hepatology. 1997 Oct;26(4):980-5. doi: 10.1002/hep.510260427. Hepatology. 1997. PMID: 9328323

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results